164 related articles for article (PubMed ID: 22937170)
1. Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors.
Huang X; Wang L; Zhang H; Wang H; Zhao X; Qian G; Hu J; Ge S; Fan X
PLoS One; 2012; 7(8):e44301. PubMed ID: 22937170
[TBL] [Abstract][Full Text] [Related]
2. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
[TBL] [Abstract][Full Text] [Related]
3. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.
Huang X; Jia R; Zhao X; Liu B; Wang H; Wang J; Zhou Y; Cun B; Ge S; Fan X
Br J Ophthalmol; 2012 Oct; 96(10):1331-8. PubMed ID: 22843987
[TBL] [Abstract][Full Text] [Related]
4. A novel anticancer therapy that simultaneously targets aberrant p53 and Notch activities in tumors.
Yao Y; Wang L; Zhang H; Wang H; Zhao X; Zhang Y; Zhang L; Fan X; Qian G; Hu JF; Ge S
PLoS One; 2012; 7(10):e46627. PubMed ID: 23071601
[TBL] [Abstract][Full Text] [Related]
5. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
Cun B; Song X; Jia R; Zhao X; Wang H; Ge S; Fan X
Cancer Biol Ther; 2012 Jan; 13(2):77-84. PubMed ID: 22336909
[TBL] [Abstract][Full Text] [Related]
6. Small interfering RNA (siRNA)-mediated knockdown of Notch1 suppresses tumor growth and enhances the effect of IL-2 immunotherapy in malignant melanoma.
Yang Z; Qi Y; Lu C; Zhang J; Luo R; Kang S
J BUON; 2015; 20(6):1553-64. PubMed ID: 26854453
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-based strategies enhance antitumor capability through p53-mediated downregulation of MGMT in uveal melanoma.
Li X; Yuan L; Zhao J; Yang H; Yang Y; Zhang Y; Cun B
Cancer Biol Ther; 2017 Mar; 18(3):194-199. PubMed ID: 28278076
[TBL] [Abstract][Full Text] [Related]
8. Radiation-inducible HtrA2 gene enhances radiosensitivity of uveal melanoma OCM-1 cells in vitro and in vivo.
Zhang F; Yu T; Yi CL; Sun XF
Clin Exp Ophthalmol; 2014 Nov; 42(8):761-8. PubMed ID: 24606398
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo.
Xu P; Qiu M; Zhang Z; Kang C; Jiang R; Jia Z; Wang G; Jiang H; Pu P
J Neurooncol; 2010 Mar; 97(1):41-51. PubMed ID: 19771395
[TBL] [Abstract][Full Text] [Related]
11. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
12. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
13. Notch1 is associated with the multidrug resistance of hypoxic osteosarcoma by regulating MRP1 gene expression.
Li C; Guo D; Tang B; Zhang Y; Zhang K; Nie L
Neoplasma; 2016; 63(5):734-42. PubMed ID: 27468877
[TBL] [Abstract][Full Text] [Related]
14. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
15. Efficient inhibition of uveal melanoma via ternary siRNA complexes.
Xie L; Yang Y; Shen J
Int J Pharm; 2020 Jan; 573():118894. PubMed ID: 31765784
[TBL] [Abstract][Full Text] [Related]
16. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
17. The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma.
Zhang L; He X; Li F; Pan H; Huang X; Wen X; Zhang H; Li B; Ge S; Xu X; Jia R; Fan X
J Exp Clin Cancer Res; 2018 Jan; 37(1):15. PubMed ID: 29382357
[TBL] [Abstract][Full Text] [Related]
18. Notch signaling promotes growth and invasion in uveal melanoma.
Asnaghi L; Ebrahimi KB; Schreck KC; Bar EE; Coonfield ML; Bell WR; Handa J; Merbs SL; Harbour JW; Eberhart CG
Clin Cancer Res; 2012 Feb; 18(3):654-65. PubMed ID: 22228632
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy.
Shen S; Sun CY; Du XJ; Li HJ; Liu Y; Xia JX; Zhu YH; Wang J
Biomaterials; 2015 Nov; 70():71-83. PubMed ID: 26302232
[TBL] [Abstract][Full Text] [Related]
20. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma.
Sun Q; Wang R; Wang Y; Luo J; Wang P; Cheng B
Oncol Rep; 2014 Feb; 31(2):933-9. PubMed ID: 24336972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
